Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

Eli Lilly (LLY-4.22%) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA).

Eli Lilly & Co.’s Alzheimer’s treatment was cleared in the US as the second drug to slow progression of the mind-robbing disease that afflicts 6 million Americans.

Drugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the US Food and Drug Administration plans to call a last ...

Experimental Eli Lilly Alzheimer’s drug donanemab is being readied for an FDA submission along the same regulatory path the agency used to approve Biogen’s Aduhelm. Though the Lilly drug met ...

A panel of independent advisors to the FDA recommended Eli Lilly's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year.

The Food and Drug Administration is declining to grant accelerated approval to an experimental Alzheimer’s drug made by the pharmaceutical company Eli Lilly, saying the agency needs safety data ...

Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration had rejected accelerated approval of its experimental Alzheimer's drug because it had not submitted enough trial data from ...

An outside panel of advisers to the Food and Drug Administration (FDA) will meet next month to discuss a new Alzheimer’s drug from Eli Lilly, the company said Tuesday. The panel will meet Jun… ...

Eli Lilly said Thursday that it is nearly ready to take another shot at getting regulatory approval for a possible Alzheimer’s drug.The drugmaker plans to submit its potential treatment ...